Used in research and development for targeted cancer therapies, particularly in prostate cancer due to its specific binding to PSMA expressed on prostate tumor cells. Enables detection and imaging of prostate tumors through conjugation with diagnostic agents. Supports the development of monoclonal antibodies and antibody-drug conjugates by providing a stable, soluble form of the target antigen for screening and optimization. Facilitates immunogenicity studies and vaccine design by serving as a recombinant antigen for immune response evaluation.